Rituximab improves interstitial lung disease in rheumatoid arthritis patients

Barbero, M.A. Nieto; Font, Cristina; Alcalá, Mariara Calderón; Font, J.; Bobillo, Juan Rigual; Freites, D.; Alcázar, L.

doi:10.1183/1393003.congress-2017.pa893

Search citation statements

Order By: Relevance

Paper Sections

Select...

Group 15: Diffuse Parenchymal Lung Disease1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evidence for wide use of rituximab in the management of connective tissue disease-associated ILD is growing. In 31 cases of rheumatoid arthritis-associated ILD, rituximab was able to stabilise lung functional decline and joint manifestations in a consistent proportion of patients [ 80 ]; in inflammatory myopathies, clinical and radiological stability was achieved in five out of seven patients. Neither study reported any severe adverse event [ 81 ].…”

Section: Group 15: Diffuse Parenchymal Lung Diseasementioning

confidence: 99%

European Respiratory Society International Congress 2017: highlights from the Clinical Assembly

Kahn

Mekov

Fregonese³

et al. 2018

ERJ Open Res

View full text Add to dashboard Cite

This article contains highlights and a selection of the scientific advances from the European Respiratory Society's Clinical Assembly (Assembly 1 and its six respective groups) that were presented at the 2017 European Respiratory Society International Congress in Milan, Italy. The most relevant topics from each of the groups will be discussed, covering a wide range of areas including clinical problems, rehabilitation and chronic care, thoracic imaging, interventional pulmonology, diffuse and parenchymal lung diseases, and general practice and primary care. In this comprehensive review, the newest research and actual data as well as award-winning abstracts and highlight sessions will be discussed.

show abstract

Section: Group 15: Diffuse Parenchymal Lung Diseasementioning

confidence: 99%